Skip to search formSkip to main contentSkip to account menu

ledipasvir

Known as: Carbamic Acid, N-((1S)-1-(((6S)-6-(5-(9,9-difluoro-7-(2-((1R,3S,4S)-2-((2S)-2-((methoxycarbonyl)amino)-3-methyl-1-oxobutyl)-2-azabicyclo(2.2.1)hept-3-yl)-1H-benzimidazol-6-yl)-9H-fluoren-2-yl)-1H-imidazol-2-yl)-5-azaspiro(2.4)hept-5-yl)carbonyl)-2-methylpropyl)-, Methyl Ester, methyl [(2S)-1-{(6S)-6-[4-(9,9-difluoro-7-{2-[(1R,3S,4S)-2-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}-2-azabicyclo[2.2.1]hept-3-yl]-1H-benzimidazol-5-yl}-9H-fluoren-2-yl)-1H-imidazol-2-yl]-5-azaspiro[2.4]hept-5-yl}-3-methyl-1-oxobutan-2-yl]carbamate 
An orally available inhibitor of the hepatitis C virus (HCV) non-structural protein 5A (NS5A) replication complex, with potential activity against… 
National Institutes of Health

Related topics

Related topics

9 relations

Broader (3)

Antiviral AgentsBenzimidazolesFluorenes
Breast Cancer Resistance Protein Inhibitors [MoA]Hepatitis Cledipasvir / sofosbuvirledipasvir 90 MG / sofosbuvir 400 MG Oral Tablet [Harvoni]

Narrower (2)

GS-5885Harvoni

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Sofosbuvir with NS5A inhibitors in hepatitis C virus infection with severe renal insufficiency
Treatment of Hepatitis C virus (HCV) in patients with severe renal insufficiency is cumbersome as sofosbuvir is mainly excreted… 
Review
2018
Review
2018
Hepatitis B reactivation after HCV treatment with sofosbuvir/ledipasvir in a HIV-coinfected patient with previous positive anti-HBs antibody: a case report and a review of literature
Chronic hepatitis B (HBV) and C (HCV) coinfection are frequently observed in clinical practice. The interaction between HCV and… 
2017
2017
Safety and efficacy of treatment with once-daily ledipasvir/sofosbuvir (90/400 mg) for 12 weeks in genotype 1 hcv-infected patients with severe renal impairment.
2017
2017
Retreatment with sofosbuvir plus grazoprevir plus elbasvir plus ribavirin of patients with Hepatitis C virus Genotype 1 or 4 with RASs at failure of a sofosbuvir plus ledipasvir or plus daclatasvir…
67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) - Boston, MA - 2016-11-11 
2016
2016
The Safety and Efficacy of Ledipasvir/Sofosbuvir for the Treatment of a Nosocomial Outbreak of HCV in Patients with Significant Cardiovascular Disease
Background There is an unmet need for interferon-and ribavirin-free treatment for chronic HCV infection in patients with… 
2016
2016
Successful Treatment of Necrolytic Acral Erythema with Ledipasvir and Sofosbuvir
Importance: Necrolytic Acral Erythema (NAE) is a cutaneous manifestation of hepatitis C virus infection, characterized by painful… 
2016
2016
In Vitro Antiviral Activity and Resistance Profile Characterization of the Hepatitis C Virus NS 5 A Inhibitor Ledipasvir
Ledipasvir (LDV; GS-5885), a component of Harvoni (a fixed-dose combination of LDV with sofosbuvir [SOF]), is approved to treat… 
2015
2015
Real-world effectiveness of Ledipasvir/Sofosbuvir 8 weeks chronic hepatitis C treatment
• 8w LDV/SOF is predominantly prescribed according to the EMA label1 for treatment-naïve non-cirrhotic CHC patients, with the… 
2015
2015
Ledipasvir and sofosbuvir:Interferon free therapy for hepatitis C virus genotype 1 infection
Hepatitis C virus(HCV) has infected more than 200 million people around the globe. From 2001-2011, interferon plus ribavirin… 
2015
2015
Increasing Access to Hepatitis C Treatment in Rwanda: The Promise ofRwandas Existing HIV Infrastructure
For decades, access to treatment for hepatitis C virus (HCV) has been limited in low-resource settings. Untreated chronic HCV…